Novartis AG

SWX:NOVN Stock Report

Market Cap: CHF 183.4b

Novartis Valuation

Is NOVN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of NOVN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: NOVN (CHF91.71) is trading below our estimate of fair value (CHF265.71)

Significantly Below Fair Value: NOVN is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NOVN?

Key metric: As NOVN is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for NOVN. This is calculated by dividing NOVN's market cap by their current earnings.
What is NOVN's PE Ratio?
PE Ratio17.6x
EarningsUS$11.76b
Market CapUS$206.41b

Price to Earnings Ratio vs Peers

How does NOVN's PE Ratio compare to its peers?

The above table shows the PE ratio for NOVN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average35.1x
ROG Roche Holding
19.2x11.1%CHF 205.2b
DESN Dottikon ES Holding
41.1xn/aCHF 3.3b
COPN Cosmo Pharmaceuticals
15.7x17.2%CHF 1.0b
LONN Lonza Group
64.6x23.9%CHF 37.0b
NOVN Novartis
17.6x7.0%CHF 183.4b

Price-To-Earnings vs Peers: NOVN is good value based on its Price-To-Earnings Ratio (17.6x) compared to the peer average (35.1x).

Price to Earnings Ratio vs Industry

How does NOVN's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
NOVN 17.6xIndustry Avg. 20.7xNo. of Companies7PE01224364860+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: NOVN is good value based on its Price-To-Earnings Ratio (17.6x) compared to the European Pharmaceuticals industry average (20.7x).

Price to Earnings Ratio vs Fair Ratio

What is NOVN's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NOVN PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio17.6x
Fair PE Ratio28.3x

Price-To-Earnings vs Fair Ratio: NOVN is good value based on its Price-To-Earnings Ratio (17.6x) compared to the estimated Fair Price-To-Earnings Ratio (28.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst NOVN forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 91.71
CHF 103.85
+13.2%
9.4%CHF 121.74CHF 86.96n/a19
Nov ’25CHF 95.49
CHF 101.39
+6.2%
9.4%CHF 118.72CHF 84.80n/a19
Oct ’25CHF 96.81
CHF 99.03
+2.3%
9.1%CHF 114.46CHF 85.16n/a19
Sep ’25CHF 102.12
CHF 97.78
-4.3%
9.8%CHF 113.82CHF 80.50n/a20
Aug ’25CHF 98.58
CHF 101.16
+2.6%
10.3%CHF 118.70CHF 83.96n/a20
Jul ’25CHF 96.72
CHF 99.52
+2.9%
11.3%CHF 118.94CHF 76.04n/a20
Jun ’25CHF 93.17
CHF 98.24
+5.4%
10.8%CHF 117.30CHF 75.97n/a19
May ’25CHF 89.05
CHF 98.98
+11.1%
11.2%CHF 119.11CHF 74.61n/a18
Apr ’25CHF 87.37
CHF 97.95
+12.1%
11.5%CHF 115.90CHF 74.48n/a18
Mar ’25CHF 90.14
CHF 96.18
+6.7%
11.3%CHF 112.69CHF 73.48n/a18
Feb ’25CHF 90.54
CHF 94.50
+4.4%
11.1%CHF 109.90CHF 74.57n/a18
Jan ’25CHF 84.87
CHF 90.96
+7.2%
10.2%CHF 106.89CHF 73.97n/a18
Dec ’24CHF 85.38
CHF 91.69
+7.4%
10.7%CHF 108.52CHF 72.86n/a18
Nov ’24CHF 85.21
CHF 95.13
+11.6%
10.5%CHF 111.59CHF 75.42CHF 95.4918
Oct ’24CHF 93.87
CHF 102.41
+9.1%
10.9%CHF 118.23CHF 81.87CHF 96.8118
Sep ’24CHF 89.35
CHF 100.83
+12.8%
9.8%CHF 114.09CHF 81.59CHF 102.1218
Aug ’24CHF 91.07
CHF 99.49
+9.3%
10.1%CHF 112.21CHF 80.24CHF 98.5817
Jul ’24CHF 90.00
CHF 97.84
+8.7%
9.8%CHF 110.68CHF 79.87CHF 96.7216
Jun ’24CHF 88.06
CHF 97.81
+11.1%
9.3%CHF 111.76CHF 80.71CHF 93.1719
May ’24CHF 91.13
CHF 95.31
+4.6%
9.5%CHF 108.68CHF 80.63CHF 89.0519
Apr ’24CHF 83.76
CHF 90.78
+8.4%
10.5%CHF 107.30CHF 79.17CHF 87.3720
Mar ’24CHF 78.60
CHF 92.36
+17.5%
10.6%CHF 107.98CHF 70.40CHF 90.1421
Feb ’24CHF 80.22
CHF 88.37
+10.2%
10.1%CHF 103.42CHF 69.57CHF 90.5421
Jan ’24CHF 83.59
CHF 86.89
+3.9%
11.4%CHF 103.77CHF 69.93CHF 84.8721
Dec ’23CHF 84.10
CHF 86.17
+2.5%
10.7%CHF 101.83CHF 70.18CHF 85.3821
Nov ’23CHF 80.71
CHF 89.60
+11.0%
11.0%CHF 107.25CHF 69.99CHF 85.2121

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Roche Holding

CHF 205.2b

Engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania.

ROG

CHF 255.80

7D

-2.8%

1Y

7.7%

Roche Holding

CHF 205.2b

Engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania.

RO

CHF 269.20

7D

-5.5%

1Y

6.4%

Bristol-Myers Squibb

US$100.3b

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.

BMY

US$54.24

7D

0%

1Y

0%